AMEX · AZTR

Azitra Inc.

$0.13 -$0.00 (-0.55%) 1D After hours

Key Metrics

$2.06M
Market cap
P/E · TTM
$0
Revenue · TTM
−$11.81M
Net income
EPS · TTM $-5.97
Dividend yield
Free cash flow
Beta · 1Y 0.39
EBITDA · TTM −$11.66M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Mar 23 high, the share price fell 58%.

    Peak close $0.30 on Mar 23; trough close $0.13 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -58%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 22
    The stock moved +34.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 22
  • Mar 20
    The stock moved +60.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 20

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.06M
Enterprise value
Shares outstanding16.2M
52-wk range$0.10 – $1.46
Avg volume · 20D2.6M
Net cash
Book value / share$5.30
IndustryPharmaceutical Preparations
ExchangeAMEX
About Azitra Inc.
IPO dateJun 16, 2023
Employees13

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -146.0% · -2,752.1%

Financial Health

Current ratio6.94
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$9.21M

Cash Flow · TTM

Operating CF −$10.63M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-9.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings